

Nigeria

Support for Vaccine: Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme

1.	Country:	Nigeria														
2.	Vaccine grant number:	NGA-IPV-R,NGA-IPV-R-VAC,NGA-IPV-R-VIG,NGA-IPV-R-VIG-UNIC														
3.	Date of Decision Letter:	21 November 2019														
4.	Date of the Partnership Framework Agreement:	09 January 2014														
5.	Programme title:	New Vaccine Support (NVS), Inactivated Polio Vaccine (IPV), Routine														
6.	Vaccine type:	Inactivated Polio Vaccine (IPV)														
7.	Requested product presentation and formulation of vaccine:	<i>IPV, 5 doses/vial, liquid,IPV, 10 doses/vial, liquid</i> <i>Requested product presentation and formulation of vaccine:</i>														
8.	Programme duration:¹	2014-2020														
9.	Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)														
		2014-2019	2020	2021	2022	2023	2024	Total ²								
	Programme Budget(US\$)	64,742,795	19,136,000	-	-	-	-	83,878,795								
10.	Vaccine introduction grant:	<table border="1" style="width: 100%; border-collapse: collapse; margin-left: 40px;"> <thead> <tr> <th colspan="3" style="text-align: center;">Approval</th> </tr> <tr> <th style="width: 25%;">Year</th> <th style="width: 45%;">Grant number</th> <th style="width: 30%;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">2014</td> <td style="text-align: center;">NGA-IPV-R-VIG-UNIC</td> <td style="text-align: center;">5,847,947</td> </tr> </tbody> </table>						Approval			Year	Grant number	Amount (US\$)	2014	NGA-IPV-R-VIG-UNIC	5,847,947
Approval																
Year	Grant number	Amount (US\$)														
2014	NGA-IPV-R-VIG-UNIC	5,847,947														
11.	Product switch grant:	Not applicable														

¹This is the entire duration of the programme.

²This is the total amount endorsed by Gavi for the entire duration of the programme.

³This is the amount that Gavi has approved.

12. Indicative annual amounts:³ (subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2014-2019	2020	2021
Number of vaccine doses	-	8,466,800	-
Number of AD syringes	-	7,450,800	-
Number of re-constitution syringes	-	-	-
Number of safety boxes	-	81,975	-
Annual Amounts (US\$)	63,448,245	19,135,566	-

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement:
Not applicable

15. Co-financing obligations:
Not applicable

Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.

16. Operational support for campaigns:
Not applicable

17. Additional Reporting Requirements:

Reports and other information :	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:	
<ul style="list-style-type: none"> • vaccine stock levels including buffer stock, by end of March; • number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. • Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March</p> <p>15 May</p>
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications: Country shall provide the following clarifications to Gavi* :

Not applicable

*** Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.**

19. Other conditions:

Not applicable

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.



Thabani Maphosa
Managing Director
Country Programmes
Gavi, the Vaccine Alliance

